Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Medicina Interna
versión impresa ISSN 0872-671X
Resumen
NUNES, Ana Luísa et al. A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin. Medicina Interna [online]. 2021, vol.28, n.4, pp.30-34. Epub 01-Dic-2021. ISSN 0872-671X. https://doi.org/10.24950/rspmi.cc.131.4.2021.
Drug induced liver injury (DILI) is a condition with a wide clinical spectrum. The diagnosis represents a challenge not only due to the large number of known hepatotoxic products but especially when the substance involved is not known to induce liver damage. Empagliflozin is linked to several adverse effects but has not been convincingly associated to DILI. We report a case of a 70-year-old type 2 diabetic woman that presented with gastrointestinal symptoms 1 month after empagliflozin introduction. Elevated hepatic enzymes were found and despite ultrasound evidence of vesicular microlithiasis, no biliary obstruction was confirmed. Other causes of liver injury were excluded and the diagnosis of DILI secondary to empagliflozin was made after liver biopsy. Complete clinical and laboratorial resolution was verified after empagliflozin withdrawal. Only two cases of DILI were reported since empagliflozin licensure which makes this case more interesting, alerting clinicians to an early diagnosis and appropriate treatment.
Palabras clave : Chemical and Drug Induced Liver Injury; Sodium-Glucose Transporter 2 Inhibitors/adverse effects..